Unknown

Dataset Information

0

The Role of Genetic Testing in Pulmonary Fibrosis: A Perspective From the Pulmonary Fibrosis Foundation Genetic Testing Work Group.


ABSTRACT: Patients with familial pulmonary fibrosis represent a subset of patients with pulmonary fibrosis in whom inherited gene variation predisposes them to disease development. In the appropriate setting, genetic testing allows for personalized assessment of disease, recognition of clinically relevant extrapulmonary manifestations, and assessing susceptibility in unaffected relatives. However currently, the use of genetic testing is inconsistent, partly because of the lack of guidance regarding high-yield scenarios in which the results of genetic testing can inform clinical decision-making. To address this, the Pulmonary Fibrosis Foundation commissioned a genetic testing work group comprising pulmonologists, geneticists, and genetic counselors from the United States to provide guidance on genetic testing in patients with pulmonary fibrosis. This CHEST special feature presents a concise review of these proceedings and reviews pulmonary fibrosis susceptibility, clinically available genetic testing methods, and clinical scenarios in which genetic testing should be considered.

SUBMITTER: Newton CA 

PROVIDER: S-EPMC9424324 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Role of Genetic Testing in Pulmonary Fibrosis: A Perspective From the Pulmonary Fibrosis Foundation Genetic Testing Work Group.

Newton Chad A CA   Oldham Justin M JM   Applegate Carolyn C   Carmichael Nikkola N   Powell Karen K   Dilling Dan D   Schmidt Shelley L SL   Scholand Mary Beth MB   Armanios Mary M   Garcia Christine Kim CK   Kropski Jonathan A JA   Talbert Janet J  

Chest 20220323 2


Patients with familial pulmonary fibrosis represent a subset of patients with pulmonary fibrosis in whom inherited gene variation predisposes them to disease development. In the appropriate setting, genetic testing allows for personalized assessment of disease, recognition of clinically relevant extrapulmonary manifestations, and assessing susceptibility in unaffected relatives. However currently, the use of genetic testing is inconsistent, partly because of the lack of guidance regarding high-y  ...[more]

Similar Datasets

| S-EPMC10878386 | biostudies-literature
| S-EPMC5470751 | biostudies-literature
| S-EPMC7170056 | biostudies-literature
| S-EPMC8305941 | biostudies-literature
| S-EPMC9777433 | biostudies-literature
| S-EPMC7503310 | biostudies-literature
| S-EPMC4337021 | biostudies-literature
| S-EPMC3552342 | biostudies-literature
| S-EPMC9796064 | biostudies-literature
2003-07-16 | GSE485 | GEO